Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012966977> ?p ?o ?g. }
- W2012966977 endingPage "225" @default.
- W2012966977 startingPage "217" @default.
- W2012966977 abstract "Background Eg5 is a microtubule motor protein that functions in bipolar spindle assembly. We investigated the relationship between Eg5 expression and the response to chemotherapy of patients with advanced non-small cell lung cancer (NSCLC). Patients and methods Eg5 expression was investigated immunohistochemically in 122 formalin-fixed tumor samples from untreated stage IIIB or IV NSCLC patients. We also investigated cyclin B1 expression, which is involved in the G2/M transition. All patients received antimitotic agents combined with platinum chemotherapy. The response to chemotherapy was compared in relation to Eg5 and cyclin B1 expression and in relation to clinicopathological factors. Results The response rate to chemotherapy of patients with Eg5-positive tumors was 37%, as opposed to 10% for patients with Eg5-negative tumors, and Eg5 expression was significantly associated with the response to chemotherapy (P = 0.002). The response rate of patients with cyclin B1-positive tumors (53%) was higher than that of patients with cyclin B1-negative tumors (23%) (P = 0.009), and Eg5 expression was significantly correlated with cyclin B1 expression (P = 0.005). A multivariate analysis confirmed Eg5 status to be an independent variable related to response to chemotherapy (P = 0.008). Conclusions Eg5 expression can predict a response to antimitotic agents combined with platinum chemotherapy among patients with advanced NSCLC. Eg5 is a microtubule motor protein that functions in bipolar spindle assembly. We investigated the relationship between Eg5 expression and the response to chemotherapy of patients with advanced non-small cell lung cancer (NSCLC). Eg5 expression was investigated immunohistochemically in 122 formalin-fixed tumor samples from untreated stage IIIB or IV NSCLC patients. We also investigated cyclin B1 expression, which is involved in the G2/M transition. All patients received antimitotic agents combined with platinum chemotherapy. The response to chemotherapy was compared in relation to Eg5 and cyclin B1 expression and in relation to clinicopathological factors. The response rate to chemotherapy of patients with Eg5-positive tumors was 37%, as opposed to 10% for patients with Eg5-negative tumors, and Eg5 expression was significantly associated with the response to chemotherapy (P = 0.002). The response rate of patients with cyclin B1-positive tumors (53%) was higher than that of patients with cyclin B1-negative tumors (23%) (P = 0.009), and Eg5 expression was significantly correlated with cyclin B1 expression (P = 0.005). A multivariate analysis confirmed Eg5 status to be an independent variable related to response to chemotherapy (P = 0.008). Eg5 expression can predict a response to antimitotic agents combined with platinum chemotherapy among patients with advanced NSCLC." @default.
- W2012966977 created "2016-06-24" @default.
- W2012966977 creator A5001727127 @default.
- W2012966977 creator A5033435047 @default.
- W2012966977 creator A5037461196 @default.
- W2012966977 creator A5038375140 @default.
- W2012966977 creator A5038813552 @default.
- W2012966977 creator A5046015782 @default.
- W2012966977 creator A5052865562 @default.
- W2012966977 creator A5058549884 @default.
- W2012966977 creator A5091584502 @default.
- W2012966977 date "2006-11-01" @default.
- W2012966977 modified "2023-10-16" @default.
- W2012966977 title "Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy" @default.
- W2012966977 cites W163275813 @default.
- W2012966977 cites W1934425437 @default.
- W2012966977 cites W1935885922 @default.
- W2012966977 cites W1964326201 @default.
- W2012966977 cites W1980923728 @default.
- W2012966977 cites W1985701763 @default.
- W2012966977 cites W1988678729 @default.
- W2012966977 cites W1993312546 @default.
- W2012966977 cites W1996402807 @default.
- W2012966977 cites W1998899128 @default.
- W2012966977 cites W2020142573 @default.
- W2012966977 cites W2029178312 @default.
- W2012966977 cites W2037139573 @default.
- W2012966977 cites W2048618706 @default.
- W2012966977 cites W2052132055 @default.
- W2012966977 cites W2075277027 @default.
- W2012966977 cites W2096986950 @default.
- W2012966977 cites W2117196140 @default.
- W2012966977 cites W2125793053 @default.
- W2012966977 cites W2130419731 @default.
- W2012966977 cites W2133492742 @default.
- W2012966977 cites W2139248078 @default.
- W2012966977 cites W2153988632 @default.
- W2012966977 cites W2160059044 @default.
- W2012966977 cites W4239714259 @default.
- W2012966977 doi "https://doi.org/10.1016/j.lungcan.2006.06.018" @default.
- W2012966977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16934364" @default.
- W2012966977 hasPublicationYear "2006" @default.
- W2012966977 type Work @default.
- W2012966977 sameAs 2012966977 @default.
- W2012966977 citedByCount "42" @default.
- W2012966977 countsByYear W20129669772012 @default.
- W2012966977 countsByYear W20129669772013 @default.
- W2012966977 countsByYear W20129669772014 @default.
- W2012966977 countsByYear W20129669772015 @default.
- W2012966977 countsByYear W20129669772016 @default.
- W2012966977 countsByYear W20129669772017 @default.
- W2012966977 countsByYear W20129669772018 @default.
- W2012966977 countsByYear W20129669772019 @default.
- W2012966977 countsByYear W20129669772020 @default.
- W2012966977 countsByYear W20129669772021 @default.
- W2012966977 countsByYear W20129669772022 @default.
- W2012966977 countsByYear W20129669772023 @default.
- W2012966977 crossrefType "journal-article" @default.
- W2012966977 hasAuthorship W2012966977A5001727127 @default.
- W2012966977 hasAuthorship W2012966977A5033435047 @default.
- W2012966977 hasAuthorship W2012966977A5037461196 @default.
- W2012966977 hasAuthorship W2012966977A5038375140 @default.
- W2012966977 hasAuthorship W2012966977A5038813552 @default.
- W2012966977 hasAuthorship W2012966977A5046015782 @default.
- W2012966977 hasAuthorship W2012966977A5052865562 @default.
- W2012966977 hasAuthorship W2012966977A5058549884 @default.
- W2012966977 hasAuthorship W2012966977A5091584502 @default.
- W2012966977 hasConcept C120504264 @default.
- W2012966977 hasConcept C121608353 @default.
- W2012966977 hasConcept C126322002 @default.
- W2012966977 hasConcept C143998085 @default.
- W2012966977 hasConcept C204232928 @default.
- W2012966977 hasConcept C2776256026 @default.
- W2012966977 hasConcept C2776694085 @default.
- W2012966977 hasConcept C2778239845 @default.
- W2012966977 hasConcept C2778437423 @default.
- W2012966977 hasConcept C2781451048 @default.
- W2012966977 hasConcept C29537977 @default.
- W2012966977 hasConcept C502942594 @default.
- W2012966977 hasConcept C71924100 @default.
- W2012966977 hasConceptScore W2012966977C120504264 @default.
- W2012966977 hasConceptScore W2012966977C121608353 @default.
- W2012966977 hasConceptScore W2012966977C126322002 @default.
- W2012966977 hasConceptScore W2012966977C143998085 @default.
- W2012966977 hasConceptScore W2012966977C204232928 @default.
- W2012966977 hasConceptScore W2012966977C2776256026 @default.
- W2012966977 hasConceptScore W2012966977C2776694085 @default.
- W2012966977 hasConceptScore W2012966977C2778239845 @default.
- W2012966977 hasConceptScore W2012966977C2778437423 @default.
- W2012966977 hasConceptScore W2012966977C2781451048 @default.
- W2012966977 hasConceptScore W2012966977C29537977 @default.
- W2012966977 hasConceptScore W2012966977C502942594 @default.
- W2012966977 hasConceptScore W2012966977C71924100 @default.
- W2012966977 hasIssue "2" @default.
- W2012966977 hasLocation W20129669771 @default.
- W2012966977 hasLocation W20129669772 @default.
- W2012966977 hasOpenAccess W2012966977 @default.
- W2012966977 hasPrimaryLocation W20129669771 @default.